ARTICLE SUMMARY:
Bigfoot Biomedical is working to develop an artificial pancreas (AP) system that combines best-in-class devices and algorithms on a secure, highly connected, and highly automated platform, making it the first truly patient-, physician- and payor-friendly AP.
With FDA’s earlier-than-expected approval last month of Medtronic plc’s 670G hybrid (treat-to-range) closed-loop insulin delivery system, the artificial pancreas (AP) concept—not so long ago, just a futuristic idea—has taken a huge step forward (see Sidebar, “ Medtronic and Abbott Score Important FDA Approvals in Diabetes Device Space ”).
